Neurogene Inc. Investment Income, Net
Neurogene Inc. (NGNE) reported Investment Income, Net of $19.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2022-03-01
- Neurogene Inc. investment income, net for the quarter ending 2020-03-31 was $434.00K, a 3.56% decline year-over-year.
- Neurogene Inc. investment income, net for the quarter ending 2019-12-31 was $264.00K, a 43.83% decline year-over-year.
- Neurogene Inc. investment income, net for the quarter ending 2019-09-30 was $392.00K, a 16.42% decline year-over-year.
- Neurogene Inc. investment income, net for the quarter ending 2019-06-30 was $436.00K, a 15.96% increase year-over-year.
- Neurogene Inc. investment income, net for fiscal 2021 was $19.00K, a 96.12% decline from fiscal 2020.
- Neurogene Inc. investment income, net for fiscal 2020 was $490.00K, a 68.22% decline from fiscal 2019.
- Neurogene Inc. investment income, net for fiscal 2019 was $1.54M, a 1.34% decline from fiscal 2018.
- Neurogene Inc. investment income, net for fiscal 2018 was $1.56M, a 56.61% increase from fiscal 2017.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2021-12-31 | $19.00K 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $490.00K 10-K · filed 2022-03-01 | |||
| 2020-03-31 | $434.00K 10-Q · filed 2020-05-06 | $698.00K derived: sum of 2 quarters · filed 2021-03-25 | $1.09M derived: sum of 3 quarters · filed 2021-03-25 | $1.53M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | $264.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $656.00K derived: sum of 2 quarters · filed 2021-03-25 | $1.09M derived: sum of 3 quarters · filed 2021-03-25 | $1.54M 10-K · filed 2021-03-25 |
| 2019-09-30 | $392.00K 10-Q · filed 2019-11-13 | $828.00K derived: sum of 2 quarters · filed 2019-11-13 | $1.28M 10-Q · filed 2019-11-13 | $1.75M derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-06-30 | $436.00K 10-Q · filed 2019-08-01 | $886.00K 10-Q · filed 2019-08-01 | $1.36M derived: sum of 3 quarters · filed 2020-05-06 | $1.82M derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-03-31 | $450.00K 10-Q · filed 2020-05-06 | $920.00K derived: sum of 2 quarters · filed 2020-05-06 | $1.39M derived: sum of 3 quarters · filed 2020-05-06 | $1.76M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $470.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $939.00K derived: sum of 2 quarters · filed 2020-03-12 | $1.31M derived: sum of 3 quarters · filed 2020-03-12 | $1.56M 10-K · filed 2020-03-12 |
| 2018-09-30 | $469.00K 10-Q · filed 2019-11-13 | $845.00K derived: sum of 2 quarters · filed 2019-11-13 | $1.09M 10-Q · filed 2019-11-13 | $1.37M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $376.00K 10-Q · filed 2019-08-01 | $624.00K 10-Q · filed 2019-08-01 | $902.00K derived: sum of 3 quarters · filed 2020-03-12 | $1.14M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $248.00K 10-Q · filed 2019-05-07 | $526.00K derived: sum of 2 quarters · filed 2020-03-12 | $762.00K derived: sum of 3 quarters · filed 2020-03-12 | $1.01M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $514.00K derived: sum of 2 quarters · filed 2020-03-12 | $764.00K derived: sum of 3 quarters · filed 2020-03-12 | $998.00K 10-K · filed 2020-03-12 |
| 2017-09-30 | $236.00K 10-Q · filed 2018-11-07 | $486.00K derived: sum of 2 quarters · filed 2018-11-07 | $720.00K 10-Q · filed 2018-11-07 | $948.00K derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $250.00K 10-Q · filed 2018-08-08 | $484.00K 10-Q · filed 2018-08-08 | $712.00K derived: sum of 3 quarters · filed 2019-03-07 | $854.00K derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $234.00K 10-Q · filed 2018-05-08 | $462.00K derived: sum of 2 quarters · filed 2019-03-07 | $604.00K derived: sum of 3 quarters · filed 2019-03-07 | $732.00K derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $228.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $370.00K derived: sum of 2 quarters · filed 2019-03-07 | $498.00K derived: sum of 3 quarters · filed 2019-03-07 | $619.00K 10-K · filed 2019-03-07 |
| 2016-09-30 | $142.00K 10-Q · filed 2017-11-08 | $270.00K derived: sum of 2 quarters · filed 2017-11-08 | $391.00K 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $128.00K 10-Q · filed 2017-08-08 | $249.00K 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $121.00K 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $108.00K 10-K · filed 2018-03-12 | |||
| 2014-12-31 | $91.00K 10-K · filed 2017-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |